The healthcare technology company said its board is reviewing Kendall’s recommendations after his mandate ended and will seek a new chief executive officer as soon as practically possible.
ARCpoint Inc. said Peter Kendall has stepped down as Interim Chief Executive Officer after completing his mandate and delivering his assessment and recommendations to the board. Kendall had been appointed on June 9, 2026 for an initial 90-day term to review the company’s business model, its MyARCpointLabs platform, commercial relationships, assets and strategic direction, and to recommend commercial and financial paths forward. The board said it is now considering those recommendations as it determines the company’s next steps and plans to appoint a new chief executive officer as soon as practically possible. The company also said the 4,000,000 restricted share units, or RSUs (share-based compensation awards), announced for Kendall on June 9 have been prorated to reflect the portion of the term he served, reducing the grant to 2,000,000 RSUs. Each RSU can be settled into one Class A Subordinate Voting Share upon vesting, which is scheduled for 12 months after June 9, 2026. The award remains subject to TSX Venture Exchange, or TSXV (Canadian junior exchange), acceptance, available plan capacity, participant limits, TSXV Policy 4.4, applicable securities laws and, if needed, disinterested shareholder approval. ARCpoint said Kendall will continue to provide advisory consulting services, preserving his eligibility under the company’s omnibus security-based compensation plan pending vesting. The company describes itself as a healthcare technology business that owns and develops MyARCpointLabs, a multi-tenant software platform for clinical lab ordering, scheduling and results delivery used by laboratories, collection sites and other healthcare providers in the United States.